Immunic, Inc. | WebDisclosure

Switch to English

8296	Sociétés
114902	Mots-clés
55328	Articles
62458	Communiqués

Accueil
Sociétés
Immunic, Inc.

BRÈVE

publiée le 07/03/2024 à 12:35, il y a 8 mois 14 jours

Immunic, Inc. annonce sa participation aux prochaines conférences scientifiques et investisseurs

Immunic, Inc. Maladies Auto-immunes Conférence Des Investisseurs Conférence Scientifique Inflammatoire Chronique
BRÈVE

publiée le 07/03/2024 à 12:35, il y a 8 mois 14 jours

Immunic, Inc. Announces Participation in Upcoming Investor and Scientific Conferences

Investor Conference Immunic, Inc. Autoimmune Diseases Scientific Conference Chronic Inflammatory
COMMUNIQUÉ DE PRESSE

publié le 07/03/2024 à 12:30, il y a 8 mois 14 jours

Immunic to Participate in Investor and Scientific Conferences in March
Immunic, Inc. (Nasdaq: IMUX) announces participation in investor and scientific conferences in March, presenting abstracts and posters showcasing their clinical pipeline of therapies for inflammatory and autoimmune diseases

Investor Conference Biotechnology Clinical Pipeline Scientific Conference Immunic Inc
COMMUNIQUÉ DE PRESSE

publié le 29/02/2024 à 12:30, il y a 8 mois 21 jours

Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
Immunic presents data from phase 2 CALLIPER and CALVID-1 trials of vidofludimus calcium at ACTRIMS Forum 2024. Positive results on serum neurofilament levels and EBV reactivation

Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials ACTRIMS Forum
BRÈVE

publiée le 29/02/2024 à 12:30, il y a 8 mois 21 jours

Immunic, Inc. Presents Phase 2 Trial Data on Vidofludimus Calcium at ACTRIMS 2024 Forum

ACTRIMS Forum 2024 Multiple Sclerosis Immunic Vidofludimus Calcium Phase 2 Trials
BRÈVE

publiée le 29/02/2024 à 12:30, il y a 8 mois 21 jours

Immunic, Inc. présente les données des essais de Phase 2 sur le Vidofludimus Calcium au Forum ACTRIMS 2024

Sclérose En Plaques Immunic Vidofludimus Calcium Essais De Phase 2 Forum ACTRIMS 2024
BRÈVE

publiée le 22/02/2024 à 12:30, il y a 8 mois 28 jours

Immunic, Inc. annonce ses résultats financiers annuels 2023 et une mise à jour corporative

Immunic, Inc. Résultats Financiers Annuels Maladies Inflammatoires Sclérose En Plaques Thérapies Orales
BRÈVE

publiée le 22/02/2024 à 12:30, il y a 8 mois 28 jours

Immunic, Inc. announces its 2023 annual financial results and corporate update

Immunic, Inc. Annual Financial Results Inflammatory Diseases Multiple Sclerosis Oral Therapies
COMMUNIQUÉ DE PRESSE

publié le 22/02/2024 à 12:30, il y a 8 mois 28 jours

Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
Immunic, Inc. reports year end 2023 financial results and provides corporate update, including strengthened balance sheet and upcoming clinical milestones. Webcast scheduled for February 22, 2024

Financial Results Webcast Corporate Update Immunic Inc. Clinical Milestones
COMMUNIQUÉ DE PRESSE

publié le 15/02/2024 à 12:30, il y a 9 mois 6 jours

Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
Immunic, Inc. to announce financial results and corporate update for the year ended December 31, 2023. Webcast on February 22, 2024, at 8:00 am ET

Financial Results Webcast Corporate Update Immunic Inc. Clinical Pipeline

Les Echos

Publié le 21/11/2024 à 06:58, il y a 6 heures 40 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 40 minutes

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Publié le 21/11/2024 à 06:58, il y a 6 heures 40 minutes

Netto-actiefwaarde per aandeel stijgt in zes maanden met 9,4% tot EUR 55,6 dankzij aanhoudend sterke groeiprestaties van portefeuille
Publié le 20/11/2024 à 20:07, il y a 17 heures 31 minutes

Entech : Nouveaux objectifs stratégiques à moyen-terme et Chiffre d’Affaires du 1er semestre 2024
Publié le 20/11/2024 à 19:20, il y a 18 heures 18 minutes

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting

Voir tout LES ECHOS COMFI WIRE

Accesswire

Publié le 21/11/2024 à 13:00, il y a 38 minutes

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Publié le 21/11/2024 à 13:00, il y a 38 minutes

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Publié le 21/11/2024 à 13:00, il y a 38 minutes

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Publié le 21/11/2024 à 13:00, il y a 38 minutes

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Publié le 21/11/2024 à 13:00, il y a 38 minutes

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

Voir tout ACCESSWIRE

EQS Group

Publié le 21/11/2024 à 13:15, il y a 23 minutes

NOTICE OF ANNUAL GENERAL MEETING
Publié le 21/11/2024 à 12:35, il y a 1 heure 3 minutes

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Publié le 21/11/2024 à 12:15, il y a 1 heure 23 minutes

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Publié le 21/11/2024 à 12:06, il y a 1 heure 32 minutes

IVU AG publishes Quarterly Report Q3-2024
Publié le 21/11/2024 à 12:00, il y a 1 heure 38 minutes

Holding(s) in Company